Neupogen (filgrastim) / Kyowa Kirin, Amgen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neupogen (filgrastim) / Kyowa Kirin, Amgen
NCT04156828: Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Terminated
1
12
US
Copanlisib, 1032568-63-0, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Gemcitabine, dFdCyd, Difluorodeoxycytidine, 1-(2-Oxo-4-amino-1, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Nealorin, Novoplatinum, Paraplatin, Paraplatine, Platinwas, Ribocarbo, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin Depot, Auricularum, Auxiloson, Baycadron, Baycuten, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone, Deltafluorene, Desameton, Dexa-Mamallet, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Rituximab, 174722-31-7, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, rituximab-abbs, RTXM83, Truxima, Pegfilgrastim, 208265-92-3, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Nyvepria, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Udenyca, Ziextenzo
University of Washington, Bayer
Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
04/22
06/23
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
NCT04584112: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed
1
83
Europe, US, RoW
Tiragolumab, Atezolizumab, Tecentriq, Nab-paclitaxel, Abraxane, Carboplatin, Doxorubicin, Lipodox, Doxil, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), filgrastim, pegfilgrastim, Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Hoffmann-La Roche
Triple-Negative Breast Cancer
03/23
03/23
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Active, not recruiting
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
10/24
SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
42
US
Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples
St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
07/23
07/25
NCT03107988: NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Active, not recruiting
1
65
Europe, Canada, US
Lorlatinib, PF06463922, Cyclophosphamide, Cytoxan, Topotecan, SKF-104864,Hycamtin®, Filgrastim/pegfilgrastim
New Approaches to Neuroblastoma Therapy Consortium, Pfizer, University of Southern California, Solving Kids' Cancer US/EU, Children's Neuroblastoma Cancer Foundation, The Band of Parents, The Evan Foundation, Wade's Army, Ronan Thompson Foundation, The Catherine Elizabeth Blair Memorial Foundation, Cookies for Kids' Cancer
Neuroblastoma
12/24
12/25
CarMob, NCT03909412: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Suspended
1
18
US
Carfilzomib, Kyprolis, Cyclophosphamide, Cytoxan, Dexamethasone, Decadron, Granulocyte Colony-Stimulating Factor, G-CSF, Filgrastim, Neupogen
Hackensack Meridian Health, Amgen
Multiple Myeloma
12/24
12/24
PRESERVE, NCT05170828: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn
1
30
NA
Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Total Body Irradiation, TBI, Busulfan, Busulfelx, Mesna, Mesnex, Sirolimus, Mycophenolate Mofetil, MMF, Filgrastim, G-CSF, Bone Marrow Transplant, Hematopoietic Stem Cell Transplant
Ossium Health, Inc., Center for International Blood and Marrow Transplant Research
Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia
03/24
11/24
NCT05088356: Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting
1
40
US
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Beneflur, SH T 586, fludarabine monophosphate, Melphalan, Melphalanum, CliniMACS CD34 Reagent System, Tacrolimus, Prograf, Advagraf, fujimycin, Cyclophosphamide, alkylating agent, Plerixafor, Mozobil, AMD 3100, LM-3100, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, filgrastim XM02, Thiotepa, Tepandina, Mycophenolate Mofetil (MMF), CellCept, Ruxolitinib, Jakafi
Stanford University, Orca Biosystems, Inc.
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
12/25
12/25
NCT04231877: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Suspended
1
50
US
Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, 174722-31-7, 687451, ABP 798, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-C2B8 Monoclonal Antibody, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, rituximab-abbs, Rituximab Biosimilar SIBP-02, Riabni, Rituximab ARRX, Rituximab PVVR, Ruxience, Prednisone, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Metacortandracin, Meticorten, Ofisolona, Panafcort, Paracort, Predicor, Predicorten, Prednidib, Prednilonga, Prednitone, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Filgrastim-aafi, Nivestym
University of Washington, Genentech, Inc.
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
12/26
12/31
NCT05330377: GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Withdrawn
1
15
US
Gilteritinib 40 MG Oral Tablet, Xospata, Cladribine, Leustatin, Cytarabine, cytosine arabinoside (Ara-C), Filgrastim, GCSF, Filgrastim sndz, Mitoxantrone, Novantrone
Ayman H Qasrawi, Astellas Pharma Inc
Acute Myeloid Leukemia
05/27
05/32

Download Options